Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells
- 6 November 2006
- journal article
- Published by Springer Nature in Oncogene
- Vol. 26 (19) , 2759-2768
- https://doi.org/10.1038/sj.onc.1210076
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid tumor progression, high metastatic potential and profound chemoresistance. We recently reported that induction of a chemoresistant phenotype in the PDAC cell line PT45-P1 by long-term chemotherapy involves an increased interleukin 1 beta (IL1)-dependent secretion of nitric oxide (NO) accounting for efficient caspase inhibition. In the present study, we elucidated the involvement of L1CAM, an adhesion molecule previously found in other malignancies, in this NO-dependent chemoresistance. Chemoresistant PT45-P1res cells, but not chemosensitive parental PT45-P1 cells, express high levels of L1CAM in an IL-dependent fashion. PT45-P1res cells subjected to short interfering RNA (siRNA)-mediated L1CAM knock-down exhibited reduced inducible nitric oxide synthase expression and NO secretion, as well as a significant increase of anti-cancer drug-induced caspase activation, an effect reversed by the NO donor S-nitroso-N-acetyl-D,L-penicillamine. Conversely, overexpression of L1CAM in PT45-P1 cells conferred anti-apoptotic protection to anti-cancer drug treatment. Interestingly, L1CAM ectodomain shedding, in example, by ADAM10, as reported for other L1CAM-related activities, seemed to be dispensable for anti-apoptotic protection by L1CAM. Neither the shedded L1CAM ectodomain was detected in chemoresistant L1CAM-expressing PT45-P1 cells nor did the administration of various metalloproteinase inhibitors affect L1CAM-dependent chemoresistance. Immunohistochemical analysis revealed L1CAM expression in 80% of pancreatic cancer specimens, supporting a potential role of L1CAM in the malignancy of this tumor. These findings substantiate our understanding of the molecular mechanisms leading to chemoresistance in PDAC cells and indicate the importance of L1CAM in this scenario.Keywords
This publication has 25 references indexed in Scilit:
- Erratum: Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1β and NO lead to inactivation of caspasesOncogene, 2006
- The adhesion molecule L1 (CD171) promotes melanoma progressionInternational Journal of Cancer, 2006
- Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody TreatmentCancer Research, 2006
- L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin/γ-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite OutgrowthMolecular and Cellular Biology, 2005
- Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesisJournal of Neurochemistry, 2005
- L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancersThe Journal of cell biology, 2005
- Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1βCancer Research, 2004
- Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicinOncogene, 2001
- Structural and Functional Evolution of the L1 Family: Are Four Adhesion Molecules Better Than One?Molecular and Cellular Neuroscience, 2000
- The Putative Apoptosis Inhibitor IEX-1L Is a Mutant Nonspliced Variant of p22PRG1/IEX-1 and Is Not Expressed in VivoBiochemical and Biophysical Research Communications, 1999